Ashley Anderson, MD
Neuromuscular Medicine · Houston, TXNPI 1487034062
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 23.3%. 2025 is the largest year on record at $34,861, more than ten times the $196 reported in 2020.
Across 212 payments — averaging $358.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$18K
- Janssen Scientific Affairs, LLC$16K
- Amgen$14K
- AstraZeneca$12K
- Argenx US, Inc.$8K
- Johnson & Johnson$5K
- plus $2K from 20 others
What the payments were for
- Consulting fees$45,35960%
- Speaking & faculty fees$22,96330%
- Travel & lodging$1,9483%
- Food & beverage$5,5637%
- Education$1320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 18 | $17,688 |
| Janssen Scientific Affairs, LLC | 14 | $16,309 |
| Amgen | 16 | $14,122 |
| AstraZeneca(2 entities) | 36 | $12,371 |
| Argenx US, Inc. | 21 | $8,474 |
| Johnson & Johnson | 4 | $4,811 |
| AbbVie(2 entities) | 25 | $462 |
| Novartis | 26 | $409 |
| CSL Behring | 9 | $233 |
| Pfizer | 9 | $180 |
| Lilly USA, LLC | 6 | $148 |
| Lundbeck LLC | 2 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $116 |
| Catalyst Pharmaceuticals, Inc. | 4 | $94 |
| Alnylam Pharmaceuticals Inc. | 1 | $73 |
| Averitas Pharma Inc. | 3 | $56 |
| Genentech USA, Inc. | 2 | $47 |
| EMD Serono, Inc. | 2 | $42 |
| Grifols USA, LLC | 2 | $33 |
| GE HealthCare | 2 | $32 |
| Octapharma USA, Inc. | 1 | $27 |
| Sanofi | 1 | $24 |
| Hospira, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Biogen | 1 | $17 |
| GRT US Holding, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromuscular medicine providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 26 | $973,124 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 74 | $563,179 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 42 | $451,539 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 70 | $353,220 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 25 | $207,774 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 16 | $183,147 |
| Kesimpta PenOfatumumab | 15 | $134,126 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $92,208 |
| Pyridostigmine Bromide | 152 | $40,299 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $21,240 |
| UbrelvyUbrogepant | 12 | $19,032 |
| Mycophenolate Mofetil | 100 | $13,021 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $11,013 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 18 | $8,414 |
| Riluzole | 35 | $7,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga, Octagam | $180 | $659,31367 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $116 | $563,17974 claims |
| Grifols USA, LLCGamunex-C | $33 | $353,22070 claims |
| CSL BehringPrivigen | $233 | $92,20818 claims |
| AbbVieUbrelvy | $462 | $19,03212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Texason file to place this against a meaningful peer group, so we don't.
Other neuromuscular medicine in Houston
- Suur BilicilerHouston$37K
- Anita MadanHouston$3K
- Nicolaas AndersonHouston$42
- Yessar HussainAustin$127K
- Matthew WicklundSan Antonio$110K
- Ratna Bhavaraju SankaSan Antonio$56K
- Hakam AsaadDallas$8K
- Darine KassarSugar Land$6K
- Niloofar YariDallas$5K
- George CreelTemple$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.